{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T02:49:16Z","timestamp":1780109356665,"version":"3.54.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2008,5,27]],"date-time":"2008-05-27T00:00:00Z","timestamp":1211846400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2008,8]]},"DOI":"10.1007\/s00198-008-0629-8","type":"journal-article","created":{"date-parts":[[2008,5,26]],"date-time":"2008-05-26T11:15:23Z","timestamp":1211800523000},"page":"1109-1117","source":"Crossref","is-referenced-by-count":23,"title":["Management of patients with Paget\u2019s disease: a consensus document of the Belgian Bone Club"],"prefix":"10.1007","volume":"19","author":[{"given":"J.-P.","family":"Devogelaer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Bergmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-J.","family":"Body","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Boutsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Goemaere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-M.","family":"Kaufman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-Y.","family":"Reginster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Rozenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Boonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,5,27]]},"reference":[{"key":"629_CR1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/095952877706000105","volume":"60","author":"J Paget","year":"1877","unstructured":"Paget J (1877) On a form of chronic inflammation of bones (Osteitis Deformans). Med Chir Trans Lond 60:37\u201363","journal-title":"Med Chir Trans Lond"},{"key":"629_CR2","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1136\/bmj.312.7029.491","volume":"312","author":"D Hosking","year":"1996","unstructured":"Hosking D, Meunier PJ, Ringe HD, Reginster J-Y, Gennari C (1996) Fortnightly review: Paget\u2019s disease of bone: diagnosis and management. Br Med J 312:491\u2013494","journal-title":"Br Med J"},{"key":"629_CR3","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1056\/NEJM199702203360807","volume":"336","author":"PD Delmas","year":"1997","unstructured":"Delmas PD, Meunier PJ (1997) Drug therapy: the management of Paget\u2019s disease of bone. N Engl J Med 336:558\u2013566","journal-title":"N Engl J Med"},{"issue":"8","key":"629_CR4","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1359\/jbmr.2001.16.8.1379","volume":"16","author":"KW Lyles","year":"2001","unstructured":"Lyles KW, Siris ES, Singer FR, Meunier PJ (2001) Perspective. A clinical approach to diagnosis and management of Paget\u2019s disease of bone. J Bone Miner Res 16(8):1379\u20131387","journal-title":"J Bone Miner Res"},{"issue":"3","key":"629_CR5","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S8756-3282(02)00817-7","volume":"31","author":"PL Selby","year":"2002","unstructured":"Selby PL, Davie MWJ, Ralston SH, Stone MD (2002) Guidelines on the management of Paget\u2019s disease of bone. Bone 31(3):10\u201319","journal-title":"Bone"},{"key":"629_CR6","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1093\/rheumatology\/keh037","volume":"43","author":"A Scarsbrook","year":"2004","unstructured":"Scarsbrook A, Brown M, Wilson D (2004) UK guidelines on management of Paget\u2019s disease of bone. Rheumatology 43:399\u2013400","journal-title":"Rheumatology"},{"key":"629_CR7","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1093\/rheumatology\/keh243","volume":"43","author":"AL Langston","year":"2004","unstructured":"Langston AL, Ralston SH (2004) Management of Paget\u2019s disease of bone. Rheumatology 43:955\u2013959","journal-title":"Rheumatology"},{"key":"629_CR8","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1056\/NEJMcp060278","volume":"355","author":"MP Whyte","year":"2006","unstructured":"Whyte MP (2006) Paget\u2019s disease of bone. N Engl J Med 355:593\u2013600","journal-title":"N Engl J Med"},{"key":"629_CR9","unstructured":"US Department of Health and Human Services. Agency for Health care policy and research (1993) Acute pain management: operative or medical procedures and trauma. Clinical Practice Guidelines n\u00b01. AHCPR Publication # 92\u20130023, p 107"},{"key":"629_CR10","first-page":"2139","volume-title":"Rheumatology, vol 2","author":"JP Devogelaer","year":"2003","unstructured":"Devogelaer JP, Nagant de Deuxchaisnes C (2003) Paget\u2019s disease of bone. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH (eds). Rheumatology, vol 2, 3rd edn. Mosby, London, pp 2139\u20132147","edition":"3"},{"key":"629_CR11","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1136\/bmj.1.6070.1181","volume":"1","author":"DJ Barker","year":"1977","unstructured":"Barker DJ, Clough PW, Guyer PB, Gardner MJ (1977) Paget\u2019s disease of bone in 14 British towns. Br Med J 1:1181\u20131183","journal-title":"Br Med J"},{"key":"629_CR12","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1359\/jbmr.1999.14.2.192","volume":"14","author":"C Cooper","year":"1999","unstructured":"Cooper C, Schafheutle K, Dennison E, Kellingray S, Guyer P, Barker D (1999) The epidemiology of Paget\u2019s disease in Britain: is the prevalence decreasing ? J Bone Miner Res 14:192\u2013197","journal-title":"J Bone Miner Res"},{"key":"629_CR13","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s00223-004-0281-z","volume":"75","author":"HR Cundy","year":"2004","unstructured":"Cundy HR, Gamble G, Wattie D, Rutland M, Cundy T (2004) Paget\u2019s disease of bone in New Zealand: continued decline in disease severity. Calcif Tissue Int 75:358\u2013364","journal-title":"Calcif Tissue Int"},{"key":"629_CR14","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S8756-3282(01)00674-3","volume":"30","author":"AA Morales-Piga","year":"2002","unstructured":"Morales-Piga AA, Bachiller-Corral FJ, Abraira V, Beltran J, Rapado A (2002) Is clinical expressiveness of Paget\u2019s disease of bone decreasing ? Bone 30:399\u2013403","journal-title":"Bone"},{"issue":"Suppl 2","key":"629_CR15","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1002\/jbmr.5650140220","volume":"14","author":"A Rapado","year":"1999","unstructured":"Rapado A, Jimenez J, Morales A, Carbonell J, Del Pino J (1999) Patterns of diagnosis of Paget\u2019s disease in Spain. J Bone Miner Res 14 [Suppl 2]:S96\u2013S98","journal-title":"J Bone Miner Res"},{"key":"629_CR16","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S8756-3282(00)00333-1","volume":"27","author":"RD Tiegs","year":"2000","unstructured":"Tiegs RD, Lohse CM, Wollan PC, Melton LJ (2000) Long-term trends in incidence of Paget\u2019s disease of bone. Bone 27:423\u2013427","journal-title":"Bone"},{"key":"629_CR17","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1359\/JBMR.050518","volume":"20","author":"L Gennari","year":"2005","unstructured":"Gennari L, Di Stefano M, Merlotti D et al (2005) Prevalence of Paget\u2019s disease of bone in Italy. J Bone Miner Res 20:1845\u20131850","journal-title":"J Bone Miner Res"},{"key":"629_CR18","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1136\/bmj.285.6347.1005","volume":"285","author":"FM Detheridge","year":"1982","unstructured":"Detheridge FM, Guyer PB, Barker DJP (1982) European distribution of Paget\u2019s disease of bone. Br Med J 285:1005\u20131008","journal-title":"Br Med J"},{"issue":"Suppl 2","key":"629_CR19","doi-asserted-by":"crossref","first-page":"P31","DOI":"10.1359\/jbmr.06s206","volume":"21","author":"GJA Lucas","year":"2006","unstructured":"Lucas GJA, Daroszewskia A, Ralston SH (2006) Contribution of genetic factors to the pathogenesis of Paget\u2019s disease of bone and related disorders. J Bone Miner Res 21 [Suppl 2]:P31\u2013P37","journal-title":"J Bone Miner Res"},{"key":"629_CR20","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0140-6736(56)90422-6","volume":"2","author":"DH Collins","year":"1956","unstructured":"Collins DH (1956) Paget\u2019s disease of bone. Incidence and subclinical forms. Lancet 2:51\u201357","journal-title":"Lancet"},{"key":"629_CR21","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1002\/art.1780231008","volume":"23","author":"RD Altman","year":"1980","unstructured":"Altman RD (1980) Musculoskeletal manifestations of Paget\u2019s disease of bone. Arthritis Rheum 23:1121\u20131127","journal-title":"Arthritis Rheum"},{"issue":"Suppl 3","key":"629_CR22","first-page":"S292","volume":"18","author":"S Fernandez","year":"2007","unstructured":"Fernandez S, Tiessen L, Powell-Tuck J, Beck S, Johansen A (2007) Pagetic hip fracture. How big is the problem? Osteoporos Int 18 [Suppl 3]:S292","journal-title":"Osteoporos Int"},{"issue":"Suppl 2","key":"629_CR23","doi-asserted-by":"crossref","first-page":"P28","DOI":"10.1359\/jbmr.06s205","volume":"21","author":"M Sundaram","year":"2006","unstructured":"Sundaram M (2006) Imaging of Paget\u2019s disease and fibrous dysplasia. J Bone Miner Res 21 [Suppl 2]:P28\u2013P30","journal-title":"J Bone Miner Res"},{"key":"629_CR24","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/00003086-198704000-00012","volume":"217","author":"B Maldague","year":"1987","unstructured":"Maldague B, Malghem J (1987) Dynamic radiologic patterns of Paget\u2019s disease of bone. Clin Orthop 217:126\u2013151","journal-title":"Clin Orthop"},{"issue":"Suppl 5","key":"629_CR25","doi-asserted-by":"crossref","first-page":"489S","DOI":"10.1016\/8756-3282(95)00260-2","volume":"17","author":"PJ Meunier","year":"1995","unstructured":"Meunier PJ, Vignot E (1995) Therapeutic strategy in Paget\u2019s disease of bone. Bone 17 [Suppl 5]:489S\u2013491S","journal-title":"Bone"},{"issue":"suppl 2","key":"629_CR26","doi-asserted-by":"crossref","first-page":"P94","DOI":"10.1359\/jbmr.06s218","volume":"21","author":"ES Siris","year":"2006","unstructured":"Siris ES, Lyles KW, Singer FR, Meunier PJ (2006) Medical management of Paget\u2019s disease of bone. Indications for treatment and review of current therapies. J Bone Miner Res 21 [Suppl 2]:P94\u2013P98","journal-title":"J Bone Miner Res"},{"key":"629_CR27","volume-title":"La maladie osseuse de Paget: actualit\u00e9s","author":"C Nagant de Deuxchaisnes","year":"1989","unstructured":"Nagant de Deuxchaisnes C, Devogelaer JP (1989) Surveillance et suivi \u00e0 long terme de la maladie osseuse de Paget. In: Simon L, S\u00e9bert JL, H\u00e9risson C (eds) La maladie osseuse de Paget: actualit\u00e9s. Masson, Paris"},{"key":"629_CR28","volume-title":"Pathophysiology and treatment of Paget\u2019s disease of bone","author":"JA Kanis","year":"1998","unstructured":"Kanis JA (1998) Pathophysiology and treatment of Paget\u2019s disease of bone, 2nd edn. Dunitz, London","edition":"2"},{"key":"629_CR29","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1359\/jbmr.2002.17.3.465","volume":"17","author":"TP Staa Van","year":"2002","unstructured":"Van Staa TP, Selby P, Leufkens HGM, Lyles K, Sprafka JM, Cooper C (2002) Incidence and natural history of Paget\u2019s disease of bone in England and Wales. J Bone Miner Res 17:465\u2013471","journal-title":"J Bone Miner Res"},{"issue":"Suppl 2","key":"629_CR30","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/jbmr.5650140221","volume":"14","author":"DH Gold","year":"1999","unstructured":"Gold DH, Burchett BM, Shipp KM, Pieper CF, Lyles KW (1999) Factors associated with self-rated health in patients with Paget\u2019s disease of bone. J Bone Miner Res 14 [Suppl 2]:99\u2013102","journal-title":"J Bone Miner Res"},{"issue":"Suppl 1","key":"629_CR31","first-page":"LB1","volume":"21","author":"SH Ralston","year":"2006","unstructured":"Ralston SH, Langston AL, Campbell MK, MacLennan G, Selby PL, Fraser WD (2006) Initial results from the PRISM study: a large randomised comparative trial of intensive versus symptomatic treatment for Paget\u2019s disease. J Bone Miner Res 21 [Suppl 1]:LB1","journal-title":"J Bone Miner Res"},{"key":"629_CR32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00223-006-0184-2","volume":"80","author":"AL Langston","year":"2007","unstructured":"Langston AL, Campbell MK, Fraser WD, MacLennan G, Selby P, Ralston SH for the PRISM Trial Group (2007) Clinical determinants of quality of life in Paget\u2019s disease of bone. Calcif Tissue Int 80:1\u20139","journal-title":"Calcif Tissue Int"},{"key":"629_CR33","first-page":"894","volume":"1","author":"RG Russell","year":"1974","unstructured":"Russell RG, Smith R, Preston C, Walton RJ, Woods CG (1974) Diphosphonates in Paget\u2019s disease. Lancet 1:894\u2013898","journal-title":"Lancet"},{"key":"629_CR34","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/1529-0131(199802)41:2<354::AID-ART20>3.0.CO;2-5","volume":"41","author":"P Garnero","year":"1998","unstructured":"Garnero P, Gineyts E, Schaffer AV, Seaman J, Delmas PD (1998) Measurement of urinary excretion of nonisomerized and b-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget\u2019s disease. Arthritis Rheum 41:354\u2013360","journal-title":"Arthritis Rheum"},{"key":"629_CR35","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.bone.2004.03.023","volume":"35","author":"IR Reid","year":"2004","unstructured":"Reid IR, Davidson JS, Wattie D et al (2004) Comparative responses of bone turnover markers to bisphosphonate therapy in Paget\u2019s disease of bone. Bone 35:224\u2013230","journal-title":"Bone"},{"issue":"Suppl 2","key":"629_CR36","doi-asserted-by":"crossref","first-page":"P22","DOI":"10.1359\/jbmr.06s204","volume":"21","author":"S Shankar","year":"2006","unstructured":"Shankar S, Hosling DJ (2006) Biochemical assessment of Paget\u2019s disease of bone. J Bone Miner Res 21[Suppl 2]:P22\u2013P27","journal-title":"J Bone Miner Res"},{"key":"629_CR37","first-page":"1650","volume":"46","author":"J Installe","year":"2005","unstructured":"Installe J, Nzeusseu A, Bol A, Depresseux G, Devogelaer JP, Lonneux M (2005) 18F-fluoride PET for monitoring therapeutic response in Paget\u2019s disease of bone. J Nucl Med 46:1650\u20131658","journal-title":"J Nucl Med"},{"key":"629_CR38","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/art.1780231020","volume":"23","author":"C Nagant de Deuxchaisnes","year":"1980","unstructured":"Nagant de Deuxchaisnes C, Maldague B, Malghem J, Devogelaer JP, Huaux JP, Rombouts-Lindemans C (1980) The action of the main therapeutic regimes on Paget\u2019s disease of bone, with a note on the effect of vitamin D deficiency. Arthritis Rheum 23:1215\u20131234","journal-title":"Arthritis Rheum"},{"key":"629_CR39","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s002230010054","volume":"69","author":"L Margiloff","year":"2001","unstructured":"Margiloff L, Harris SS, Lee S, Lechan R, Dawson-Hughes B (2001) Vitamin D status of an outpatient clinic population. Calcif Tissue Int 69:263\u2013267","journal-title":"Calcif Tissue Int"},{"key":"629_CR40","first-page":"99","volume":"49","author":"M-C Chapuy","year":"1982","unstructured":"Chapuy M-C, Zucchelli P, Meunier PJ (1982) La fonction parathyro\u00efdienne dans la maladie osseuse de Paget. Rev Rhum Mal Osteoartic 49:99\u2013102","journal-title":"Rev Rhum Mal Osteoartic"},{"key":"629_CR41","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/jbmr.5650040111","volume":"4","author":"ES Siris","year":"1989","unstructured":"Siris ES, Clemens TP, McMahon D, Gordon A, Jacobs TP, Canfield RE (1989) Parathyroid function in Paget\u2019s disease of bone. J Bone Miner Res 4:75\u201379","journal-title":"J Bone Miner Res"},{"key":"629_CR42","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1365-2265.1991.tb00294.x","volume":"34","author":"AJ Fenton","year":"1991","unstructured":"Fenton AJ, Gutteridge DH, Kent GN et al (1991) Intravenous aminobisphosphonate in Paget\u2019s disease: clinical, biochemical, histomorphometric and radiological responses. Clin Endocrinol (Oxf) 34:197\u2013204","journal-title":"Clin Endocrinol (Oxf)"},{"key":"629_CR43","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S0140-6736(79)91318-7","volume":"I","author":"W Frijlink","year":"1979","unstructured":"Frijlink W, Bijvoet O, Te Velde J, Heynen G (1979) Treatment of Paget\u2019s disease with 3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.). Lancet i:799\u2013803","journal-title":"Lancet"},{"key":"629_CR44","first-page":"335","volume":"80","author":"E Siris","year":"1995","unstructured":"Siris E (1995) Paget\u2019s disease of bone. J Clin Endocrinol Metab 80:335\u2013338","journal-title":"J Clin Endocrinol Metab"},{"key":"629_CR45","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1210\/jc.2006-1404","volume":"92","author":"S Boonen","year":"2007","unstructured":"Boonen S, Lips P, Bouillon R, Bischoff-Ferrari HA, Vanderschueren D, Haentjens P (2007) Need for additional calcium to reduce the risk of hip fracture with vitamin D supplementation: evidence from a comparative metaanalysis of randomized controlled trials. J Clin Endocrinol Metab 92:1415\u20131423","journal-title":"J Clin Endocrinol Metab"},{"key":"629_CR46","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/0002-9343(74)90815-8","volume":"56","author":"J DeRose","year":"1974","unstructured":"DeRose J, Singer FR, Avramides A et al (1974) Response of Paget\u2019s disease to porcine and salmon calcitonins: effects of long-term treatment. Am J Med 56:858\u2013866","journal-title":"Am J Med"},{"key":"629_CR47","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2165\/00024677-200201040-00006","volume":"1","author":"JP Devogelaer","year":"2002","unstructured":"Devogelaer JP (2002) Modern therapy for Paget\u2019s disease of bone. Focus on bisphosphonates. Treat Endocrinol 1:241\u2013257","journal-title":"Treat Endocrinol"},{"key":"629_CR48","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1056\/NEJM199702203360807","volume":"336","author":"P Delmas","year":"1997","unstructured":"Delmas P, Meunier PJ (1997) The management of Paget\u2019s disease of bone. N Engl J Med 336:558\u2013566","journal-title":"N Engl J Med"},{"key":"629_CR49","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/0221-8747(81)90046-1","volume":"3","author":"E Siris","year":"1981","unstructured":"Siris E, Canfield R, Jacobs T, Stoddart K, Spector T (1981) Clinical and biochemical effects of EHDP in Paget\u2019s disease of bone: patterns of response to initial treatment and to long-term therapy. Metab Bone Dis Relat Res 3:301\u2013308","journal-title":"Metab Bone Dis Relat Res"},{"key":"629_CR50","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1210\/jcem-44-1-96","volume":"44","author":"R Canfield","year":"1977","unstructured":"Canfield R, Rosner W, Skinner J et al (1977) Diphosphonate therapy of Paget\u2019s disease of bone. J Clin Endocrinol Metab 44:96\u2013106","journal-title":"J Clin Endocrinol Metab"},{"key":"629_CR51","doi-asserted-by":"crossref","first-page":"656","DOI":"10.7326\/0003-4819-87-6-656","volume":"87","author":"MRA Khairi","year":"1977","unstructured":"Khairi MRA, Altman RD, DeRosa GP, Zimmermann J, Schenk RK, Johnston CC (1977) Sodium etidronate in the treatment of Paget\u2019s disease of bone. A study of long-term results. Ann Intern Med 87:656\u2013663","journal-title":"Ann Intern Med"},{"key":"629_CR52","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/0002-9343(85)90055-5","volume":"79","author":"RD Altman","year":"1985","unstructured":"Altman RD (1985) Long-term follow-up of therapy with intermittent etidronate disodium in Paget\u2019s disease of bone. Am J Med 79:583\u2013590","journal-title":"Am J Med"},{"key":"629_CR53","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/S0140-6736(85)92253-6","volume":"1","author":"AJP Yates","year":"1985","unstructured":"Yates AJP, Percival RC, Gray RES et al (1985) Intravenous clodronate in the treatment and retreatment of Paget\u2019s disease of bone. Lancet 1:1474\u20131477","journal-title":"Lancet"},{"key":"629_CR54","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1359\/jbmr.1998.13.6.1032","volume":"13","author":"ES Siris","year":"1998","unstructured":"Siris ES, Chines AA, Altman RD et al (1998) Risedronate in the treatment of Paget\u2019s disease of bone: an open label, multicenter study. J Bone Miner Res 13:1032\u20131038","journal-title":"J Bone Miner Res"},{"key":"629_CR55","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0002-9343(96)00227-6","volume":"101","author":"I Reid","year":"1996","unstructured":"Reid I, Nicholson GC, Weinstein R (1996) Biochemical and radiologic improvement in Paget\u2019s disease of bone treated with alendronate: a randomized, placebo-controlled trial. Am J Med 101:341\u2013348","journal-title":"Am J Med"},{"key":"629_CR56","first-page":"755","volume":"64","author":"RES Gray","year":"1987","unstructured":"Gray RES, Yates AJP, Preston CJ, Smith R, Russell RGG, Kanis JA (1987) Duration of effect of oral diphosphonate therapy in Paget\u2019s disease of bone. Q J Med 64:755\u2013767","journal-title":"Q J Med"},{"key":"629_CR57","first-page":"961","volume":"81","author":"E Siris","year":"1996","unstructured":"Siris E, Weinstein RS, Altman R et al (1996) Comparative study of alendronate versus etidronate for the treatment of Paget\u2019s disease of bone. J Clin Endocrinol Metab 81:961\u2013967","journal-title":"J Clin Endocrinol Metab"},{"key":"629_CR58","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1002\/art.1780380620","volume":"38","author":"C Roux","year":"1995","unstructured":"Roux C, Gennari C, Farrerons J et al (1995) Comparative prospective, double-blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget\u2019s disease of bone. Arthritis Rheum 38:851\u2013858","journal-title":"Arthritis Rheum"},{"key":"629_CR59","first-page":"206","volume":"25","author":"P Peris","year":"2007","unstructured":"Peris P, Alvarez L, Vidal S, Martinez MA, Monegal A, Gua\u00f1abens N (2007) Treatment with tiludronate has a similar effect to risedronate on Paget\u2019s disease activity assessed by bone markers and bone scintigraphy. Clin Exp Rheum 25:206\u2013210","journal-title":"Clin Exp Rheum"},{"key":"629_CR60","doi-asserted-by":"crossref","unstructured":"Miller PD, Brown JP, Siris ES, Hoseyni MS, Axelrod DW, Bekker PJ, for the Paget\u2019s risedronate\/etidronate study group (1999) A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget\u2019s disease of bone. Am J Med 106:513\u2013520","DOI":"10.1016\/S0002-9343(99)00062-5"},{"key":"629_CR61","first-page":"71","volume":"119","author":"D Thiebaud","year":"1989","unstructured":"Thiebaud D, Jaeger P, Jacquet AF, Burckhardt P (1989) Une perfusion unique de pamidronate (APD) dans la maladie de Paget de l\u2019os. Schweiz Med Wochenschr 119:71\u201374","journal-title":"Schweiz Med Wochenschr"},{"key":"629_CR62","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/0140-6736(93)92935-M","volume":"342","author":"BB Adamson","year":"1993","unstructured":"Adamson BB, Gallacher SJ, Byars J, Ralston SH, Boyle IT, Boyle BF (1993) Mineralisation defects with pamidronate therapy for Paget\u2019s disease. Lancet 342:1459\u20131460","journal-title":"Lancet"},{"key":"629_CR63","first-page":"226","volume":"308","author":"GJ Bombassei","year":"1994","unstructured":"Bombassei GJ, Yocono M, Raisz LG (1994) Effects of intravenous pamidronate therapy on Paget\u2019s disease of bone. Am J Med Sci 308:226\u2013233","journal-title":"Am J Med Sci"},{"key":"629_CR64","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1056\/NEJMoa044241","volume":"353","author":"IR Reid","year":"2005","unstructured":"Reid IR, Miller P, Lyles K et al (2005) Comparison of a single infusion of zoledronic acid with risedronate for Paget\u2019s disease. N Engl J Med 353:898\u2013908","journal-title":"N Engl J Med"},{"key":"629_CR65","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1046\/j.1523-1755.2003.00071.x","volume":"64","author":"GS Markowitz","year":"2003","unstructured":"Markowitz GS, Fine PL, Stack JI et al (2003) Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 64:281\u2013289","journal-title":"Kidney Int"},{"key":"629_CR66","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1359\/jbmr.061001","volume":"22","author":"D Hosking","year":"2007","unstructured":"Hosking D, Lyles K, Brown J et al (2007) Long-term control of bone turnover in Paget\u2019s disease with zoledronic acid and risedronate. J Bone Miner Res 22:142\u2013148","journal-title":"J Bone Miner Res"},{"key":"629_CR67","doi-asserted-by":"crossref","first-page":"A73","DOI":"10.1016\/S1098-3015(10)67367-6","volume":"8","author":"P Lecompte","year":"2005","unstructured":"Lecompte P, Devogelaer JP, Kaufman JM, Goemaere S, Geusens P, Engbersen A (2005) Cost-effectiveness analysis of Aclasta in Paget\u2019s disease of bone in Belgium. Value Health 8:A73","journal-title":"Value Health"},{"issue":"6","key":"629_CR68","doi-asserted-by":"crossref","first-page":"A220","DOI":"10.1016\/S1098-3015(10)63261-5","volume":"9","author":"AA Kurth","year":"2006","unstructured":"Kurth AA, Kotowa W, Goel D, Maiwenn JA (2006) Long-term cost-effectiveness of zoledronic acid versus risedronate in patients with Paget\u2019s disease of the bone in Germany. Value Health 9(6):A220","journal-title":"Value Health"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-008-0629-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-008-0629-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-008-0629-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T18:31:32Z","timestamp":1708972292000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-008-0629-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5,27]]},"references-count":68,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2008,8]]}},"alternative-id":["629"],"URL":"https:\/\/doi.org\/10.1007\/s00198-008-0629-8","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,5,27]]}}}